Publications by authors named "G Caldarola"
Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden.
View Article and Find Full Text PDF(1) Background/Objectives: Nail psoriasis (NP) is a chronic and difficult-to-treat disease, which causes significant social stigma and impairs the patients' quality of life. Moreover, nail psoriasis is a true therapeutic challenge for clinicians. The presence of nail psoriasis can be part of a severe form of psoriasis and can have predictive value for the development of psoriatic arthritis.
View Article and Find Full Text PDFA fixed-dose combination of calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) aerosol foam (Enstilar, LEO Pharma) is the only topical therapy approved for the acute (reactive) and proactive management of psoriasis.
View Article and Find Full Text PDFArticle Synopsis
- - Alopecia areata is an autoimmune disorder that damages hair follicles on the scalp and body, leading to hair loss.
- - Janus kinase inhibitors are effective in treating adults with this condition, while topical treatments like Brevilin-A have shown promise for children and adolescents with mild to moderate cases.
- - Brevilin-A, derived from Centipeda minima, works by blocking specific signaling pathways and has been successfully used in pediatric patients, indicating it could be a safe and effective option for challenging cases of alopecia areata in younger populations.